Cathie Wood’s ARK sells SpaceX stock, buys Nurix Therapeutics

ARK sold 348,406 SpaceX shares across ARKK, ARKQ and ARKW for $49.2 million, and also sold $12.8 million of Alphabet and $12.1 million of Eli Lilly. It bought 350,410 Nurix Therapeutics shares for $9.0 million, alongside smaller purchases of Twist Bioscience, Pacific Biosciences and GeneDx. The reported trades show portfolio reallocation from selected large technology and pharmaceutical holdings toward biotech and other innovative companies; no fund performance or broader market reaction was reported.

Analysis

Treat this as a weak positioning signal, not a change in biotech or mega-cap fundamentals. ARK’s daily transactions can reflect portfolio weights, ETF flows, or liquidity management; without fund-level AUM, prior holdings, and trade execution data, the reported buys and sells do not establish a meaningful change in conviction. In particular, selling Eli Lilly while buying smaller biotech names is not evidence that ARK expects a broad pharmaceutical-to-biotech rotation. If flows do persist, the second-order effect is likely to be concentrated in the smaller, potentially less-liquid names, where incremental buying or selling can matter more than it would for Alphabet.

The source needs verification before trading: the SpaceX transaction is presented with a ticker despite no supplied identity mapping, and the Personalis share count is malformed. Confirm the instrument, share count, and whether the reported amounts are executions rather than estimates. Near term, any price impact is likely flow- and liquidity-driven; over 1–3 months, persistence across disclosures and company-specific clinical, commercial, or guidance updates would matter more. Over 6–18 months, biotech performance will depend on evidence of durable product demand and financing conditions—not ARK’s one-day allocation. Contrarian read: investors may overinterpret a prominent manager’s trades as information about fundamentals when they may be routine portfolio mechanics.

Key Decisions for Investors

• No trade on this disclosure alone. Before sizing any position in Nurix Therapeutics, Twist Bioscience, Pacific Biosciences, Personalis, or GeneDx, verify the source data and compare the transaction with each fund’s prior holdings, AUM, and the stock’s normal trading volume.
• Use repeat activity as an alert, not an entry signal: consider a position only if subsequent disclosures confirm persistent buying and the company’s own operating or clinical evidence supports the thesis. Falsify that signal if ARK reverses the flow or company guidance/data deteriorate.
• Avoid treating the Alphabet and Eli Lilly sales as standalone short signals. Reassess only if company-specific estimates or guidance weaken; otherwise, the reported sales may be portfolio maintenance rather than a fundamental view.
• Validate the purported SpaceX/“SPCX” instrument and the malformed Personalis share count before drawing conclusions or acting on either reported transaction.